ADVANCE STUDY
A cross-sectional, non-interventional, epidemiological study of age-related comorbidities in older people with haemophilia
Identifying and researching key issues in the ageing haemophilia population
ADVANCE WORKING GROUP
The ADVANCE Working Group consists of experienced haemophilia treaters from across Europe who wish to raise awareness of issues related to the ageing haemophilia population and to consider how current management strategies should best be adapted to their needs.
Since its inception ADVANCE has developed recommendations and ongoing studies that aim to:
- Highlight key issues associated with the ageing haemophilia population
- Identify how management of age-related co-morbidities should be adapted to those with haemophilia
- Encourage the development of further research focusing on the ageing haemophilia population
- Generate recommendations that can be used by clinicians across Europe
The ADVANCE initiative and this website are sponsored by Bayer.
Copyright © Bayer plc
The images used on this site do not necessarily represent actual haemophilia patients and are for illustration purposes only.
If you want to report a side effect or quality complaint, please contact your healthcare professional (e.g. treating physician or pharmacist), your local health authority, or go to the "Contact" menu item at the Bayer website of your country (e.g. UK site: www.mhra.gov.uk/yellowcard).
Date of preparation: June 2018 Job code: G.SM.HEM.05.2015.0536
